People may experience the same disease differently. It’s essential that clinical trials include people with a variety of lived experiences and living conditions, as well as characteristics like race and ethnicity, age, sex, and sexual orientation so that all communities benefit from scientific advances.
Historically, clinical trials largely represented almost exclusively White male study participants. This shortcoming has created gaps in our understanding of diseases and conditions, preventive factors, and treatment effectiveness across populations
This clinical trial is the first written for younger Black Women with early, hormone receptor-positive clinically high-risk but genomic low-risk breast cancer. The question we intend to answer is whether this group of women can avoid chemotherapy and its harmful side effects while having the same clinical outcomes using Ovarian Function Suppression (OFS) in combination with endocrine therapy.
It starts with the majority of self-identified Black Women.
It looks at ancestry.
It allows for shared decision-making.
It addresses key life goals for Women of Color.
It seeks to understand both social determinants of health and biology.
It is written and run by minorities in medicine.
It partners with patient advocates and faith communities of color.